Valuation: Larimar Therapeutics, Inc.

Market Cap 424M 366M 344M 313M 589M 40.61B 597M 4.04B 1.58B 20.31B 1.59B 1.56B 67.64B P/E 2026 *
-3.02x
P/E 2027 * -3.34x
Enterprise Value 336M 290M 273M 248M 467M 32.2B 474M 3.2B 1.26B 16.11B 1.26B 1.23B 53.65B EV / Sales 2026 *
-
EV / Sales 2027 * 6.84x
Free-Float
98.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Larimar Therapeutics, Inc.

1 day-6.02%
1 week-5.80%
Current month+6.28%
1 month+9.73%
3 months+25.31%
6 months+37.63%
Current year+6.56%
1 week 4.05
Extreme 4.05
4.46
1 month 3.6
Extreme 3.6
4.46
Current year 2.72
Extreme 2.715
6.42
1 year 2.72
Extreme 2.715
6.42
3 years 1.61
Extreme 1.61
13.68
5 years 1.53
Extreme 1.53
15.26
10 years 1.53
Extreme 1.53
25.87
Manager TitleAgeSince
Chief Executive Officer 67 01/05/2020
Director of Finance/CFO 67 28/05/2020
Chief Tech/Sci/R&D Officer 65 17/07/2023
Director TitleAgeSince
Director/Board Member 67 01/01/2020
Chairman 61 28/05/2020
Director/Board Member 58 28/05/2020
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Buy

Director

50,000 0.0584%
27/02/26 Buy

Director

5,000 0.0058%
27/02/26 Buy

Director

100,000 0.1168%
Change 5-day change 1-year change 3-year change Capi.($)
-6.02%-5.80%+4.10%+4.91% 424M
+0.17%+4.35%+72.39%+114.97% 73.45B
+0.21%+14.56%+55.96%+91.14% 62.99B
+0.11%-3.10%+0.94%+491.16% 28.05B
-1.40%+4.81%+60.85%+20.35% 25.42B
+1.26%-0.05%-17.59%-15.96% 23.3B
+0.78%+3.93%+39.69%-15.15% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+14.80%+515.88% 16.53B
+1.53%+3.49%+40.68%+151.75% 13.16B
Average -0.76%+2.69%+51.58%+178.29% 28.09B
Weighted average by Cap. -0.05%+5.67%+56.92%+163.88%

Financials

2026 *2027 *
Net sales - 41.7M 36.02M 33.89M 30.8M 57.93M 4B 58.78M 398M 156M 2B 157M 153M 6.66B
Net income -139M -120M -113M -102M -192M -13.27B -195M -1.32B -517M -6.64B -520M -509M -22.11B -158M -137M -129M -117M -220M -15.17B -223M -1.51B -592M -7.59B -595M -582M -25.28B
Net Debt -87.7M -75.75M -71.27M -64.77M -122M -8.4B -124M -836M -328M -4.2B -329M -322M -14B -138M -120M -113M -102M -192M -13.27B -195M -1.32B -517M -6.64B -520M -509M -22.11B
Logo Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Employees
71
Date Price Change Volume
18/08/26 $4.060 -6.02% 869,633
17/08/26 $4.320 -0.92% 882,799
14/08/26 $4.360 +2.11% 1,183,071
13/08/26 $4.270 -2.29% 1,502,798
12/08/26 $4.370 +1.39% 1,180,764
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.060USD
Average target price
14.30USD
Spread / Average Target
+252.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LRMR Stock